Financials data is unavailable for this security.
View more
Year on year CNBX Pharmaceuticals Inc grew revenues -- from 0.00 to 410.17k while net income improved from a loss of 3.72m to a smaller loss of 3.71m.
| Gross margin | 14.96% |
|---|---|
| Net profit margin | -525.10% |
| Operating margin | -300.81% |
| Return on assets | -325.63% |
|---|---|
| Return on equity | -- |
| Return on investment | -- |
More ▼
Cash flow in USDView more
In 2023, CNBX Pharmaceuticals Inc increased its cash reserves by 10.36%, or 12.18k. Cash Flow from Financing totalled 100.00k or 24.38% of revenues. In addition the company used 112.52k for operations while cash from investing totalled 24.70k.
| Cash flow per share | -0.0388 |
|---|---|
| Price/Cash flow per share | -- |
| Book value per share | -0.0789 |
|---|---|
| Tangible book value per share | -0.0789 |
More ▼
Balance sheet in USDView more
| Current ratio | 0.0316 |
|---|---|
| Quick ratio | -- |
| Total debt/total equity | -- |
|---|---|
| Total debt/total capital | -- |
More ▼
Growth rates in USD
Year on year, growth in earnings per share excluding extraordinary items increased 86.19%.
| EPS growth(5 years) | -- |
|---|---|
| EPS (TTM) vs TTM 1 year ago | 97.74 |
